Home page

CARDIOPROGRESS
Foundation for the advancement of cardiology

Knowledge, observation, action

  РУС

Feedback

RU EN
  •  About Foundation 
  •  Scientific news 
  •   Events  
  •   Projects  
  •   Guidelines  
  •   Trials  
  •   Editorial activity  
  •   Archive  

International Heart and Vascular Disease Journal-Issues

International Heart and Vascular Disease Journal

Volume 1, Number 1, August 2013        
Volume 2, Number 2, February 2014        
Volume 2, Number 3, June 2014          
Volume 2, Number 4, November 2014        
Volume 3, Number 5, March 2015        
Volume 3, Number 6, June 2015        
Volume 3, Number 7, September 2015        
Volume 3, Number 8, December 2015        
Volume 4, Number 9, March 2016        
Volume 4, Number 10, June 2016        
Volume 4, Number 11, September 2016        
Volume 4, Number 12, December 2016        
Volume 5, Number 13, March 2017        
Volume 5, Number 14, June 2017        
Volume 5, Number 15, September 2017        
Volume 5, Number 16, December 2017        

Scientific news

  • Blood Pressure Variability Linked to Mortality in Patients With ANCA-Associated Vasculitis Among patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis undergoing maintenance therapy, greater visit-to-visit systolic blood pressure variability (SBPV) was independently associated with an increased risk for all-cause mortality.

  • Morphine Underused for End-of-Life Dyspnea in the Emergency Department Compared with Inpatient Care Among 250 patients presenting to the emergency department (ED) with dyspnea at the end of life, 15.2% received morphine in the ED, whereas 68% received it during subsequent inpatient care. Patients with lung cancer or a do-not-resuscitate order were more likely to receive morphine in the ED, but its use was not associated with reduced survival.

  • Present state and future of screening for atrial fibrillation: a state-of-the-art review Atrial fibrillation is the most common arrhythmia and is a leading cause of stroke and heart failure yet often remains undiagnosed. Screening has been proposed to identify asymptomatic AF and initiate preventive treatment, but evidence for reduction in hard clinical endpoints such as stroke and heart failure remains inconclusive.

  • Levosimendan versus dobutamine in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials Acute decompensated heart failure with reduced ejection fraction often requires inotropic support. While dobutamine is commonly used, its safety and efficacy remain debated. Levosimendan has emerged as a potential alternative, with distinct pharmacological properties.

  • Cardiovascular Benefits of Semaglutide in SELECT Trial Not Fully Explained by Weight Loss and Other Improvements In adults with obesity and established cardiovascular disease (CVD), semaglutide was associated with improvements in several risk factors. However, those changes only accounted for part of the reduced risk for major adverse cardiovascular events (MACE) noted in the SELECT trial.

Partners

  • The Department of Health in Moscow
  • The State Committee on Health
  • Silicea-Poligraf, publishing house

Video resource

Channel "Cardioprogress"

Follow us

Top.Mail.Ru

© 2012-2018 Foundation for the advancement of cardiology «Cardioprogress»